Paul C Trippier
Overview
Explore the profile of Paul C Trippier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
636
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Huwaimel B, Jonnalagadda S, Jonnalagadda S, Kumari S, Nocentini A, Supuran C, et al.
Drug Dev Res
. 2023 Mar;
84(4):681-702.
PMID: 36872587
Inhibition of specific carbonic anhydrase (CA) enzymes is a validated strategy for the development of agents to target cancer. The CA isoforms IX and XII are overexpressed in various human...
12.
Kumari S, Maddeboina K, Bachu R, Boddu S, Trippier P, Tiwari A
Drug Discov Today
. 2022 Jul;
27(10):103322.
PMID: 35868626
Alzheimer's disease (AD) is a detrimental neurodegenerative disease that progressively worsens with time. Clinical options are limited and only provide symptomatic relief to AD patients. The search for effective anti-AD...
13.
Morsy A, Maddeboina K, Gao J, Wang H, Valdez J, Dow L, et al.
ACS Chem Neurosci
. 2022 Jul;
13(14):2176-2190.
PMID: 35802826
Alzheimer's disease (AD) is the most common dementia affecting one in nine people over 65. Only a handful of small-molecule drugs and the anti-β amyloid (Aβ) antibody aducanumab are approved...
14.
Huwaimel B, Jonnalagadda S, Jonnalagadda S, Zahra F, Nocentini A, Supuran C, et al.
Bioorg Med Chem
. 2022 May;
67:116805.
PMID: 35635929
Angiogenesis inhibitors are a critical pharmacological tool for the treatment of solid tumors. Suppressing vascular permeability leads to inhibition of tumor growth, invasion, and metastatic potential by blocking the supply...
15.
Esfahani S, Abbruscato T, Trippier P, Karamyan V
Expert Opin Ther Targets
. 2022 May;
26(5):401-404.
PMID: 35543670
No abstract available.
16.
Rahman M, Esfahani S, Nozohouri S, Kumari S, Kocot J, Zhang Y, et al.
Bioorg Med Chem Lett
. 2022 Mar;
64:128669.
PMID: 35292343
Modulating peptidase neurolysin (Nln) has been identified as a potential cerebroprotective target for the development of therapeutics for ischemic stroke. Continued structure-activity relationship studies on peptidomimetic small molecule activators of...
17.
Jonnalagadda S, Huwaimel B, Jonnalagadda S, Garrison J, Trippier P
J Org Chem
. 2022 Mar;
87(6):4476-4482.
PMID: 35258961
Synthesis of highly strained fused substituted dihydrobenzopyran cyclopropyl lactones derived from coumarin carboxylates are reported. The substrate scope tolerates a variety of 6- and 8-substituents on the coumarin ring. Substitution...
18.
Nozohouri S, Esfahani S, Noorani B, Patel D, Villalba H, Ghanwatkar Y, et al.
Pharm Res
. 2022 Mar;
39(7):1587-1598.
PMID: 35239135
Purpose: Neurolysin (Nln) is a peptidase that functions to preserve the brain following ischemic stroke by hydrolyzing various neuropeptides. Nln activation has emerged as an attractive drug discovery target for...
19.
Ashraf-Uz-Zaman M, Ji G, Tidwell D, Yin L, Thakolwiboon S, Pan J, et al.
ACS Chem Neurosci
. 2022 Jan;
13(2):217-228.
PMID: 34978174
The dopaminergic system is involved in the regulation of immune responses in various homeostatic and disease conditions. For conditions such as Parkinson's disease and multiple sclerosis (MS), pharmacological modulation of...
20.
Rahman M, Kumari S, Esfahani S, Nozohouri S, Jayaraman S, Kinarivala N, et al.
J Med Chem
. 2021 Dec;
65(1):890.
PMID: 34935384
No abstract available.